Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: REGN17235 · Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation Trial sites expanded: 0 → 3 locations Regeneron PharmaceuticalsPhase 1 NCT07753148
  2. Minor: COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors · Diabetes Trial sites expanded: 7 → 10 locations CAPTEUR PROTECTNot applicable NCT07018180
  3. Minor: SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) Trial sites expanded: 24 → 27 locations Supira MedicalNot applicable NCT07296744
  4. Minor: Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib · High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Trial sites expanded: 258 → 262 locations National Cancer Institute (NCI)Phase 3 NCT07391774
  5. Minor: Non-Interventional Study · Limbal Stem Cell Deficiency Trial sites expanded: 8 → 21 locations Claris Biotherapeutics, Inc.Not specified NCT07636590
  6. Minor: Drug-Eluting Registry · Real-World Treatment of Lesions in the Peripheral Vasculature Trial sites expanded: 86 → 89 locations Boston Scientific CorporationNot specified NCT04674969
  7. Minor: Tornier Perform™ Reversed Monopost Study Trial sites expanded: 0 → 3 locations Stryker Trauma and ExtremitiesNot specified NCT07764614
  8. Minor: Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery Trial sites expanded: 4 → 11 locations Aesculap AGNot specified NCT05966961
  9. Minor: Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer · a Weakened Immune System Trial sites expanded: 57 → 60 locations National Cancer Institute (NCI)Phase 2 NCT07042295
  10. Minor: Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Trial sites expanded: 22 → 27 locations National Cancer Institute (NCI)Phase 2 NCT07504588
  11. Minor: Experimental Approach · Plasma Cell Leukemia, The QUANTUM Trial Trial sites expanded: 11 → 14 locations National Cancer Institute (NCI)Phase 2 NCT07605416
  12. Minor: Addition of Iberdomide to Therapy · Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Trial sites expanded: 3 → 7 locations National Cancer Institute (NCI)Phase 1/2 NCT07437963
  13. Minor: Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) Trial sites expanded: 149 → 152 locations National Cancer Institute (NCI)Phase 2 NCT06577441
  14. Minor: Histotripsy x Pancreatic Cancer Enrollment increased: 20 → 25 participants The University of Hong KongNot applicable NCT07873606
  15. Minor: Use of Ultrasound for Early Identification of Patients at Risk of Swallowing Disorders Acquired in the ICU Enrollment increased: 100 → 110 participants Centre Hospitalier Universitaire DijonNot applicable NCT05922085
  16. Minor: Vanguard Study: Testing a New Way to Screen for Cancer Trial sites expanded: 44 → 49 locations National Cancer Institute (NCI)Not applicable NCT06995898
  17. Minor: Corticosteroids in Hyperinflammatory Phenotype of Critical Illness Trial sites expanded: 1 → 11 locations Bin DuPhase 2 NCT07511582
  18. Minor: BEACON-AA · Apixaban With or Without Clopidogrel in Stroke · Atrial Fibrillation and Cerebral Atherosclerosis Trial sites expanded: 0 → 21 locations Yonsei UniversityPhase 4 NCT07237308
  19. Minor: Progressive Supranuclear Palsy Clinical Trial Platform Trial sites expanded: 21 → 24 locations Adam BoxerPhase 2 NCT07173803
  20. Minor: Effective and Safe Odronextamab is Compared to Standard of Care · Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma Study completion moved earlier from May 29, 2029 to May 29, 2028 Regeneron PharmaceuticalsPhase 3 NCT06230224
  21. Minor: Guselkumab Subcutaneous Therapy · Moderately to Severely Active Crohn's Disease Study completion moved earlier from Oct 30, 2028 to Mar 27, 2028 Janssen Research & Development, LLCPhase 3 NCT05197049
  22. Minor: ORJ-001 · IPF Start date pushed from Oct 2026 to Nov 2026 Oorja Bio, Inc.Phase 2 NCT07869147
  23. Minor: SPY072 · Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial) Start date changed from estimate of Sep 2026 to Oct 6, 2026 Spyre Therapeutics, Inc.Phase 2 NCT07766005
  24. Minor: National Registry of Noonan Syndrome Trial sites reduced: 35 → 13 locations Istituto Giannina GasliniNot specified NCT07881159
  25. Minor: Food Effect of UBT48128 Tablets in Healthy Participants Study completion pushed from Dec 30, 2026 to Mar 31, 2027 The United Bio-Technology (Hengqin) Co., Ltd.Phase 1 NCT07922798